Pharmaceutical Pipeline Submission Guidelines Deadline: Wednesday, 17 January 2024

The application will be submitted under “Pharmaceutical Pipeline” submission type. Pharmaceutical Pipeline submissions should include early clinical data (Phase 1 and 2) on compounds for which Phase 3 data has not been presented. The goal is to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms, since such data would also be of great interest.

- Pharmaceutical Pipeline submissions should be structured as: Background, Methods, Results and Discussion.
- There is a limit of 3,200 characters, not counting spaces, for the text of your abstract submission. No images, graphs, or tables will be accepted.
- Submissions by women and minorities are highly encouraged.
- Accepted Pharmaceutical Pipeline Presentations are also offered the opportunity to present a poster presentation.